The integration of locoregional with systemic adjuvant therapy for early-stage breast cancer: the shifting sands of decision-making. (March 2014)

• Record Type: Journal Article
• Authors: Fisher, Christine M; Diamond, Jennifer R; Kounalakis, Nicole; Kabos, Peter; Mayordomo, Jose; Rabinovitch, Rachel A; Murphy, Colleen; Finlayson, Christina; Borges, Virginia F; Elias, Anthony D
• Is Part Of: Breast cancer management. Volume 3:Number 2(2014)
• Page Start: 205
• Page End: 212
• Publication Date: 2014-03
• Subjects: Breast -- Cancer -- Periodicals; Breast -- Cancer -- Treatment -- Periodicals; 616.9944905
• DOI: 10.2217/bmt.13.83
• Languages: English
• ISSNs: 1758-1923

Abstract

SUMMARY Given the generally excellent outcomes for modern breast cancer treatment, the recognition that overtreatment is commonplace is the driving force to reduce the treatment impact of surgery, radiation therapy and chemotherapy. Many recent trials have demonstrated that fewer axillary lymph node dissections, smaller radiation field sizes and less administration of chemotherapy are all feasible without compromising the long-term outcomes. However, each of these trials has studied a single modality while maintaining the intensities of the other modalities. There is a natural tendency, albeit controversial, to reduce more than one modality at a time. We review the literature, and counsel the breast cancer oncologist to work as a multimodality team to decide with the patient which modality can be reduced, and which should be preserved in its intensity.